corynoxeine: active principles of Uncariae Ramulus et Uncus; structure given in first source for ((7beta,16E,20alpha)-isomer) and ((16E,20alpha)-isomer); RN given refers to ((7beta,16E,20alpha)-isomer) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 44568160 |
| CHEMBL ID | 481358 |
| SCHEMBL ID | 23259426 |
| MeSH ID | M0154563 |
| Synonym |
|---|
| corynoxeine |
| CHEMBL481358 |
| 630-94-4 |
| 27kic0q2va , |
| unii-27kic0q2va |
| corynoxan-16-carboxylic acid, 16,17,18,19-tetradehydro-17-methoxy-2-oxo-, methyl ester, (7beta,16e,20alpha)- |
| S9306 |
| AKOS016010994 |
| CS-3803 |
| spiro(3h-indole-3,1'(5'h)-indolizine)-7'-acetic acid, 6'-ethenyl-1,2,2',3',6',7',8',8'a-octahydro-.alpha.-(methoxymethylene)-2-oxo-, methyl ester, (.alpha.e,1'r,6'r,7's,8'as)- |
| .delta.18-rhynchophylline |
| corynoxan-16-carboxylic acid, 16,17,18,19-tetradehydro-17-methoxy-2-oxo-, methyl ester, (7.beta.,16e,20.alpha.)- |
| .delta.18-rhyncophylline |
| corynoxein |
| HY-N0590 |
| CCG-268431 |
| Q27254211 |
| SCHEMBL23259426 |
| methyl (e)-2-[(3r,6'r,7's,8'as)-6'-ethenyl-2-oxospiro[1h-indole-3,1'-3,5,6,7,8,8a-hexahydro-2h-indolizine]-7'-yl]-3-methoxyprop-2-enoate |
| AC-34615 |
| DTXSID001318311 |
| AS-76851 |
| delta18-rhynchophylline |
| spiro(3h-indole-3,1'(5'h)-indolizine)-7'-acetic acid, 6'-ethenyl-1,2,2',3',6',7',8',8'a-octahydro-alpha-(methoxymethylene)-2-oxo-, methyl ester, (alphae,1'r,6'r,7's,8'as)- |
| delta18-rhyncophylline |
| methyl (7beta,16e,20alpha)-17-methoxy-2-oxocorynoxa-16,18-dien-16-carboxylate |
| Excerpt | Reference | Relevance |
|---|---|---|
| " After the LC-MS method was validated, it was applied to a back-propagation artificial neural network (BP-ANN) pharmacokinetic model study of CX in rats." | ( Development of LC-MS determination method and back-propagation ANN pharmacokinetic model of corynoxeine in rat. Cai, J; Chen, H; Hu, L; Lin, G; Ma, J; Wang, X, 2014) | 0.62 |
| " Subsequently, a method of high-performance liquid chromatography coupled with triple-quadrupole mass spectrometry was established for pharmacokinetic study of YGS in rat plasma." | ( The metabolism of YiGan San and subsequent pharmacokinetic evaluation of four metabolites in rat based on liquid chromatography with tandem mass spectrometry. Chen, H; Feng, F; Gai, Y; Liu, W; Xie, N, 2014) | 0.4 |
| " The present study was undertaken to assess the plasma pharmacokinetic characteristics of major ICN metabolites, and the role of simulated gastric and intestinal fluid (SGF and SIF), human and rat liver microsomes (HLMs and RLMs), and seven recombinant human CYP enzymes in the major metabolic pathway of ICN." | ( Pharmacokinetic study of isocorynoxeine metabolites mediated by cytochrome P450 enzymes in rat and human liver microsomes. Chen, F; Kano, Y; Qi, W; Wang, H; Yuan, D; Zang, B; Zhao, L, 2016) | 0.73 |
| " The pharmacokinetic results revealed that the absorption and bioavailability of corynoxeine in depression rats decreased compared to normal rats." | ( Development of a novel UHPLC-MS/MS method for the quantification of corynoxeine: Application to pharmacokinetics and tissue distribution studies in normal and chronic unpredictable mild stress-induced depression rats. Meng, FH; Sun, Q; Wang, L; Wang, SY; Zhang, TJ; Zhao, N, 2024) | 1.9 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The pharmacokinetic results revealed that the absorption and bioavailability of corynoxeine in depression rats decreased compared to normal rats." | ( Development of a novel UHPLC-MS/MS method for the quantification of corynoxeine: Application to pharmacokinetics and tissue distribution studies in normal and chronic unpredictable mild stress-induced depression rats. Meng, FH; Sun, Q; Wang, L; Wang, SY; Zhang, TJ; Zhao, N, 2024) | 1.9 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID340409 | Inhibition of LPS-stimulated NO release in rat cortical microglial cells assessed as nitrite accumulation after 48 hrs | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Alkaloids from the leaves of Uncaria rhynchophylla and their inhibitory activity on NO production in lipopolysaccharide-activated microglia. |
| AID340407 | Inhibition of LPS-stimulated NO release in rat cortical microglial cells assessed as nitrite accumulation at 1 ug/ml after 48 hrs relative to LPS | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Alkaloids from the leaves of Uncaria rhynchophylla and their inhibitory activity on NO production in lipopolysaccharide-activated microglia. |
| AID340410 | Inhibition of LPS-stimulated NO release in rat cortical microglial cells assessed as nitrite accumulation at 100 ug/ml after 48 hrs relative to LPS | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Alkaloids from the leaves of Uncaria rhynchophylla and their inhibitory activity on NO production in lipopolysaccharide-activated microglia. |
| AID1385453 | Cytotoxicity against human HT-29 cells assessed as reduction in cell viability at 100 uM after 24 hrs by MTT assay | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Alkaloids with Immunosuppressive Activity from the Bark of Pausinystalia yohimbe. |
| AID1385454 | Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 100 uM after 24 hrs by MTT assay | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Alkaloids with Immunosuppressive Activity from the Bark of Pausinystalia yohimbe. |
| AID340405 | Cell viability of rat cortical microglial cells after 48 hrs by MTT assay | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Alkaloids from the leaves of Uncaria rhynchophylla and their inhibitory activity on NO production in lipopolysaccharide-activated microglia. |
| AID340404 | Cell viability of LPS-stimulated rat cortical microglial cells after 48 hrs by MTT assay | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Alkaloids from the leaves of Uncaria rhynchophylla and their inhibitory activity on NO production in lipopolysaccharide-activated microglia. |
| AID1385452 | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 100 uM after 24 hrs by MTT assay | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Alkaloids with Immunosuppressive Activity from the Bark of Pausinystalia yohimbe. |
| AID340408 | Inhibition of LPS-stimulated NO release in rat cortical microglial cells assessed as nitrite accumulation at 10 ug/ml after 48 hrs relative to LPS | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Alkaloids from the leaves of Uncaria rhynchophylla and their inhibitory activity on NO production in lipopolysaccharide-activated microglia. |
| AID340406 | Inhibition of NO release in rat cortical microglial cells | 2008 | Journal of natural products, Jul, Volume: 71, Issue:7 | Alkaloids from the leaves of Uncaria rhynchophylla and their inhibitory activity on NO production in lipopolysaccharide-activated microglia. |
| AID1385451 | Cytotoxicity against human MCF7 cells assessed as reduction in cell viability at 100 uM after 24 hrs by MTT assay | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Alkaloids with Immunosuppressive Activity from the Bark of Pausinystalia yohimbe. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 13 (72.22) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.34) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||